Table 4

Clinical management of patients with serrated polyposis syndrome

No. of patients who received clearing of all relevant lesions403
Time from diagnosis up to clearing (months); median (IQR)1.5 (0–8.7)
No. of patients who received surgery during clearing; n (%)95 (23.6)
Reason surgery during clearing; n (%)
 CRC56 (58.9)
 Polyp burden30 (31.6)
 Unresectable polyp8 (8.4)
 Perforation due to polypectomy1 (1.1)
No. of needed clearing colonoscopies; median (IQR)*2 (1–3)
No. of patients who received surveillance after clearing of all polyps260
Follow-up time since clearing of all polyps (years); median (IQR)†3.2 (1.6–5.7)
No. of colonoscopies during surveillance; median (IQR)†2 (1–4)
Interval between surveillance colonoscopies (years); median (IQR)†1.2 (1.0–1.6)
No. of patients who received surgery during surveillance; n (%)11 (4.2)
Reason surgery during surveillance; n (%)
 CRC1 (9.1)
 Polyp burden5 (45.4)
 Unresectable polyp4 (36.4)
 Perforation due to polypectomy1 (9.1)
Overview of detected polyps during surveillance per patient
No. of SPs; median (IQR)7 (2–18)
No. of SPs proximal to the rectosigmoid; median (IQR)2 (0–7)
No. of large SPs; median (IQR)0 (0–1)
Patients with at least 1 SP ≥10 mm; n (%)70 (26.9)
No. of adenomas; median (IQR)0 (0–2)
Patients with at least 1 adenoma; n (%)122 (46.9)
Patients with at least 1 SP ≥10 mm proximal to the rectosigmoid; n (%)65 (25.0)
Patients with at least 1 SP-containing dysplasia; n (%)16 (6.2)
Patients with at least 1 advanced adenoma; n (%)20 (7.7)
  • *Referred to the 308 patients who did not receive surgery during clearing.

  • †Referred to the 260 patients who received surveillance after clearing of all polyps.

  • CRC, colorectal cancer; SPs, serrated polyps.